Trial Profile
Modification of Vascular Disease Markers in Active Rheumatoid Arthritis with Fully Human Monoclonal Anti-TNF-alpha Antibody (Humira [Adalimumab])
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms MARVEL
- 28 Feb 2008 New trial record.